Stettner GM, Kubin L. Antagonism of orexin receptors in the posterior hypothalamus reduces hypoglossal and cardiorespiratory excitation from the perifornical hypothalamus. J Appl Physiol 114: 119 -130, 2013. First published October 25, 2012 doi:10.1152/japplphysiol.00965.2012.-The perifornical (PF) region of the posterior hypothalamus promotes wakefulness and facilitates motor activity. In anesthetized rats, local disinhibition of PF neurons by GABA A receptor antagonists activates orexin (OX) neurons and elicits a systemic response, including increases of hypoglossal nerve activity (XIIa), respiratory rate, heart rate, and blood pressure. The increase of XIIa is mediated to hypoglossal (XII) motoneurons by pathways that do not require noradrenergic or serotonergic projections. We hypothesized that the pathway might include OX-dependent activation locally within the PF region or direct projections of OX neurons to the XII nucleus. Adult, male SpragueDawley rats were urethane anesthetized, vagotomized, paralyzed, and ventilated. Gabazine (GABA A receptor antagonist, 0.18 mM, 20 nl) was injected into the PF region, and ϳ2 h later, a second gabazine injection was performed preceded by injection of a dual OX1/2 receptor antagonist (almorexant; 90 mM) either into the XII nucleus (40 -60 nl at 2-3 rostrocaudal levels; n ϭ 6 rats), or into the PF region (40 -60 nl; n ϭ 6 rats). XIIa, respiratory rate, heart rate, and arterial blood pressure were analyzed for 70 min after each gabazine injection. The excitatory effects of PF gabazine on XIIa, respiratory, and heart rates were significantly reduced by up to 44 -82% when gabazine injections were preceded by PF almorexant injections, but not when almorexant was injected into the XII nucleus. These data suggest that a significant portion of XII motoneuronal and cardiorespiratory activation evoked by disinhibition of PF neurons is mediated by local OX-dependent mechanisms within the posterior hypothalamus.
THE IMPORTANCE OF THE POSTERIOR hypothalamus in the maintenance of vigilance was first described by von Economo (22) . Decades later, lesion and pharmacological studies pointed to the perifornical (PF) region of the posterior hypothalamus as a major site for the promotion and maintenance of wakefulness (2, 54) , as well as the facilitation of motor activity (50, 68) . Within this area, neurons synthesizing the excitatory neuropeptides orexins (OX, also named hypocretins) have been discovered, with OX binding selectively to the OX1 and OX2 receptors (OX1R and OX2R) (15, 53) . Loss of OX neurons (61) and low OX levels in the cerebrospinal fluid (44) , as well as a mutation of the OX gene (47), have been described in patients with narcolepsy, a disease characterized by excessive sleepiness, sleep paralysis, hypnagogic hallucinations, and cataplexy (14) . Animal models with disrupted OX signaling have symptoms similar to narcolepsy in humans (6, 11, 37) .
The projections of OX neurons exhibit extensive divergence to all levels of the neuroaxis (13, 48, 63) , and expression of OX1R and/or OX2R mRNA has a pattern matching that of OX-containing axon terminals (41) . Both OX1R and OX2R have excitatory effects (reviewed in Ref. 56) . OX neurons themselves are under a tonic GABAergic inhibition (2, 30) . In anesthetized rats, disinhibition of PF neurons, including those containing OX, elicits a systemic response that comprises desynchronized cortical EEG, activation of hippocampal theta rhythm, increased hypoglossal (XII) nerve activity (XIIa), as well as accelerated respiratory rate and heart rate (18, 38, 65) . Also in anesthetized rats, systemic administration of a dual OX1R and OX2R antagonist, almorexant (9) , revealed that the increase of XIIa following PF disinhibition is, in part, dependent on OX transmission (26) . An indirect pathway involving brain stem noradrenergic and serotonergic neurons was initially considered as the one responsible for the increase of XIIa following PF disinhibition, because aminergic neurons are major targets of OX projections (48) and have well-established excitatory connections to XII motoneurons (4, 40, 52) . Indeed, brain stem aminergic premotoneurons have peak activity during wakefulness and the lowest activity during rapid-eyemovement sleep (5, 24, 62) and are activated by OX (8, 10, 31) . However, it has been shown that the increase of XIIa following PF disinhibition is mediated to XII motoneurons by pathways that do not require noradrenergic or serotonergic projections to the XII nucleus (25) .
OX projections and OX receptor distribution within the brain suggest other potential pathways from OX neurons to XII motoneurons. Activation of XIIa following disinhibition of OX neurons may require OX-dependent activation of non-OX neurons locally within the PF region of the posterior hypothalamus because there is a high density of OX-containing terminals and OX1R/OX2R in this area (41, 48) . In addition, OX neurons themselves express OX2R, which may allow them to form positive feedback circuits through which they may amplify their initial activation (67) . OX transmission to XII motoneurons might also be mediated by a direct hypothalamobrain stem pathway, because OX neurons have direct axonal projections to the XII nucleus (27, 48) and XII motoneurons express OX2R (41, 64) .
The hypothalamic excitatory pathways to XII motoneurons and the involved neurotransmitter systems may be important for the control of upper airway patency in obstructive sleep apnea (OSA) patients who experience repetitive, sleep-related upper airway narrowing or collapse and hypoxic episodes that disrupt ventilation and sleep (17, 49) . During wakefulness, these patients exhibit hyperactivity of upper airway muscles, including those of the tongue (43, 60) , which protects their upper airway against occlusions and allows for adequate ventilation. The basis of this clinically important compensatory mechanism is not yet fully understood, but the OX network might play a role in the compensatory hyperactivity of upper airway muscles during wakefulness in OSA patients.
To test the two hypothetical pathways that may mediate the effects of hypothalamic activation of XII motoneurons, we conducted experiments in which we locally administered the dual OX1R/OX2R antagonist, almorexant (9) , into candidate sites and measured the impact of this intervention on the activation of XIIa following injections of a GABA A receptor antagonist, gabazine, into the PF region of the posterior hypothalamus. Almorexant was injected into either the PF hypothalamus or the XII nucleus. We found that the activation of XIIa, as well as an increase of the cardiorespiratory parameters, central respiratory rate, heart rate, and blood pressure, elicited by PF gabazine injections were significantly attenuated when almorexant was injected into the hypothalamic PF region before the gabazine injection compared with the effects of gabazine injections only. In contrast, almorexant injected into the XII nucleus did not have any significant effect on the cardiorespiratory response, except a trend toward attenuation of XIIa at the tail end of the long-lasting gabazine effect. These data suggest that XII motoneuronal activation evoked from the PF region by antagonizing GABA A receptors is mediated, in part, by OX-dependent mechanisms, and that the effect requires OX-mediated activation within the PF hypothalamus.
A preliminary report has been published (59).
MATERIAL AND METHODS
Animal preparation and experimental protocol. Experiments were performed on 12 adult, male Sprague-Dawley rats [423 Ϯ 17 (SE) g] obtained from Charles River Laboratories (Wilmington, MA). All animal procedures followed the guidelines of the National Institutes of Health and were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania.
Rats were preanesthetized with isoflurane (3%), followed by urethane (1.0 g/kg iv via a tail vein catheter). They were tracheotomized and had a femoral artery and vein catheterized for arterial blood pressure monitoring and fluid/drug administration, respectively. The medial branch of the right XII nerve was dissected and cut, and its central end was placed in a cuff-type recording electrode (modified after Ref. 23 ). Both cervical vagus nerves were cut to enhance XIIa and make it independent of lung volume feedback. The animal's head was placed in a stereotaxic holder in a 13°nose-down position, and openings were made in the parietal bones for inserting a drugcontaining pipette into the posterior hypothalamus on the left side and a recording electrode into the hippocampus on the right side. Two screws were attached to the skull (2 mm anterior and 2 mm left/right from bregma) to record cortical EEG. In six animals, the caudal medulla was exposed to insert a microinjection pipette into the right XII nucleus.
The animals were paralyzed with pancuronium bromide (1 mg/kg iv, Sigma, St. Louis, MO) and artificially ventilated with an airoxygen mixture (30 -60% O 2). The central respiratory drive was set by first ventilating the animal to the apneic threshold and then gradually reducing the tidal volume of the ventilator until a steady respiratory modulation of XIIa was established. Subsequently, the rate and volume of artificial ventilation were kept constant. Adequate level of anesthesia was verified based on stability of the amplitude and constant rate of inspiratory bursts recorded from the XII nerve, stable heart rate and arterial blood pressure, and stable cortical EEG and hippocampal activities. If needed, supplemental doses of urethane were administered in 0.2-0.3 mg/kg increments. Adequate paralysis was maintained by continuous infusion of pancuronium bromide (0.6 mg·kg Ϫ1 ·h Ϫ1 iv). Rectal temperature was maintained at 37.0°C with a servo-controlled heating pad.
Hippocampal activity was recorded using an electrode made from two Teflon-insulated platinum wires (model 771000; A-M Systems, Carlsborg, WA) with tips separated by 0.8 mm. The electrode was vertically inserted into the hippocampus 3.7 mm posterior to the bregma, 2.2 mm to the right from midline, and 2.4 mm below the cortical surface.
Drug microinjections were made using glass pipettes pulled to obtain tip diameters of 25-30 m (model 626800; A-M Systems). Drugs were injected by applying pressure to the fluid in the pipette while monitoring the movement of the meniscus with a calibrated microscope with 1-nl resolution. We used gabazine (SR-95531, Sigma; 0.18 mM), a GABA A receptor antagonist, diluted from frozen aliquots in 0.9% NaCl before each experiment. The microinjection pipette was inserted into the PF region of the posterior hypothalamus aiming at the following stereotaxic coordinates: 3.1 mm caudal to the bregma, 1.3 mm lateral from midline, and 8.2 mm below the cortical surface. To mark the injection sites, gabazine solution containing 2% of Pontamine sky blue dye (ICN Biomedicals, Aurora, OH) was used. After recording of baseline parameters, the animals received two gabazine injections, 20 nl each, separated by 133 Ϯ 8 (SE) min. Almorexant (ACT-078573A, Actelion Pharmaceuticals, Allschwil, Switzerland), a dual OX1R and OX2R antagonist (9), was prepared separately for each experiment (90 mM in distilled water) and injected 39 Ϯ 6 min before the second gabazine injection either into the PF hypothalamus (40 -60 nl) or into the XII nucleus (40 -60 nl injections placed at 2 or 3 different rostrocaudal levels). The solubility of almorexant depends on the pH, which varies with the concentration. Without adding any vehicle or buffer, we were able to achieve a clear solution in distilled water at a concentration of 90 mM. This concentration considerably exceeds that required for 50% inhibition of the response, which is 13 nM and 8 nM for human OX1R and OX2R, respectively (9) . Accordingly, any partial precipitation of almorexant solution that might have occurred at the injection site(s) following contact of almorexant with extracellular fluid would still leave sufficient dose of the drug diffusing from the injection site to ensure full blockage of OX receptors. By allowing at least 30 min for the drug to diffuse, we ensured that the entire regions of interest (XII nucleus or the PF region) were exposed to a sufficient high concentration of the antagonist. For almorexant injections into the PF region of the posterior hypothalamus (n ϭ 6 rats), we used the same coordinates as for the gabazine injections. For almorexant injections into the XII nucleus (n ϭ 6 rats), we targeted the XII nucleus at two or three rostrocaudal levels to antagonize OX receptors in the entire XII nucleus. Therefore, the pipette for the first injection was placed 0.3 mm lateral to the midline, 0.15 mm rostral to the obex, and 1.15 mm below the dorsal medullary surface, followed by a second injection 0.5 mm caudal to the obex, and a third injection 0.8 mm rostral to the obex. Three injections were made in two animals. In the remaining four animals, the most rostral target was not accessible due to extension of the cerebellum beyond the desired rostrocaudal level, and two almorexant injections, 0.3 mm rostral to the obex and 0.5 mm caudal to the obex, were performed. With either two or three injections, they covered the caudal two-thirds of the XII nucleus containing the vast majority of XII motoneurons, which send their axons in the medial branch of the XII nerve (3) . Almorexant injections into the XII nucleus were completed within 19 Ϯ 7 (SE) min.
At the conclusion of the experiment, the animal received an additional dose of urethane (1.0 g/kg) and was intra-arterially perfused with 0.9% saline followed by 10% formalin. The brain was extracted, postfixed, and cryoprotected in 30% sucrose, and 50-m medullary sections were cut on a cryostat and collected sequentially. The sections containing the Pomtamine blue dye were serially mounted and stained with Neutral red for localization of the injection sites.
Data acquisition and analysis. XII nerve, hippocampal, and cortical EEG recording electrodes were connected to differential preamplifiers (NeuroLog 100, Digitimer, Hertfordshire, UK). Using NeuroLog modules 104 and 126 (Digitimer), the signals were amplified and filtered (XII nerve activity: 150 -3,000 Hz; hippocampal activity: 1-20 Hz; cortical EEG: 0.8 -100 Hz). Arterial blood pressure was measured using a pressure transducer (P23Db, Statham, Hato Rey, Puerto Rico). The raw and integrated XIIa (time constant 100 ms; moving averager MA-821RSP, CWE, Ardmore, PA), arterial blood pressure, inspiratory-expiratory CO 2 difference (Micro Capnometer, Columbus Instruments, Columbus, OH), and event markers were digitized (Micro1401-3 data acquisition unit; Cambridge Electronic Design, Cambridge, UK) and stored on a computer (Spike-2 software version 7; Cambridge Electronic Design) using a sampling rate of 2,000 Hz for the raw XIIa, 50 Hz for the hippocampal activity, and 100 Hz for all other signals. The power of hippocampal activity in the theta frequency range (2.8 -4 Hz in urethane anesthetized rats) was calculated offline in successive 10-s intervals (Spike-2 software).
In this study, we analyzed alterations of XIIa, central respiratory rate, heart rate, and mean arterial blood pressure elicited by hypothalamic gabazine. Changes of cortical EEG and hippocampal activities elicited by gabazine were continuously monitored and considered as indices of the effectiveness of gabazine injections, as reported in a previous study (38) . The effect of PF gabazine injections on XIIa was measured from integrated XIIa by calculating the area under the curve (AUC) relative to the lowest level of the moving average measured during expiration before the injections (XIIa was absent during expiration under the baseline conditions). The instantaneous central respiratory rate and heart rate were automatically derived from integrated XIIa and arterial blood pressure records, respectively. Baseline cardiorespiratory parameters (XIIa AUC, central respiratory rate, heart rate, and blood pressure) were averaged over 5-min intervals before each gabazine injection. Peak activities after gabazine injections were derived from a 1-min interval centered around the peak of the effect. Latencies to the onset and the peak of gabazine effects were separately measured for each output variable. The observation period following each gabazine injection was 70 min. During these periods, average output parameters were measured over successive 5-min intervals until minute 40 and over 10-min intervals thereafter. The excitatory effect of gabazine on XIIa over the entire observation period, and the effect of almorexant on the effects of gabazine were investigated using both the raw XIIa AUC data set and a data set that was normalized by the baseline XIIa before the first gabazine injection. For the evaluation of gabazine effects on respiratory rate and heart rate, we analyzed absolute changes from the baseline levels before gabazine injections.
Statistical analysis. Statistical analysis was performed using SigmaPlot 12.0 software (Systat Software, San Jose, CA). Normality of the distributions was tested using the Shapiro-Wilk test. The results are presented as mean Ϯ SE, unless indicated otherwise. A P value of Ͻ0.05 was considered significant.
Cardiorespiratory baseline parameters were compared between the experimental groups using the unpaired Student's t-test. For comparisons within each experimental group (baseline and peak cardiorespiratory parameters, absolute differences between baseline and peak activities, and the latencies to the onset and peak of gabazine effects), paired Student's t-tests were used in the case of normally distributed data sets. For nonnormal distributions, the Wilcoxon signed-rank test was used. Two-way, repeated-measures ANOVA with Holm-Sidak post hoc analysis was used to evaluate the impact of almorexant on cardiorespiratory activation over the entire observation period following PF hypothalamic injections of gabazine. The central respiratory rate data set for the two-way, repeated-measures ANOVA was not normally distributed. Therefore, one-way, repeated-measures ANOVA was used to analyze respiratory rate differences within each measurement period following the two gabazine injections and to compare these differences to baseline conditions (Holm-Sidak post hoc multiple comparisons). Pearson's correlation coefficient was calculated to estimate correlation between blood pressure and cardiorespiratory excitability, as well as XIIa and cardiorespiratory excitability following hypothalamic gabazine injections.
RESULTS
We investigated the impact of the dual OX1R/OX2R antagonist, almorexant, on the effect of gabazine injections into the PF region of the posterior hypothalamus on XIIa, central respiratory rate, heart rate, and blood pressure in urethaneanesthetized, paralyzed, and artificially ventilated rats. Each animal received two gabazine injections, of which the second one was preceded by almorexant injected either into the hypothalamic gabazine injection site (n ϭ 6 rats) or into the XII nucleus (n ϭ 6 rats). Figure 1 illustrates the distribution of gabazine injection sites in the PF region of the posterior hypothalamus in all experiments. All gabazine injections elicited a systemic response, which included increased XIIa, central respiratory rate, heart rate, and arterial blood pressure. In addition, cortical EEG was activated, and hippocampal thetalike rhythm was elicited, as described previously (38) . A representative response to gabazine injection is illustrated in Fig. 2 .
Impact of hypothalamic OX1R/OX2R antagonism on cardiorespiratory activation by gabazine injected into the PF hypothalamus.
The baseline levels of XIIa AUC were not different when measured in arbitrary units during a 5-min interval before the first and second gabazine injections (1.82 Ϯ 0.38 V·min vs. 2.09 Ϯ 0.56 V·min, P ϭ 0.71; Fig. 3A ). Both gabazine injections led to a significant increase of the XIIa AUC when peak levels were compared with baseline activities. XIIa AUC reached 10.31 Ϯ 2.48 V·min at the peak of the effect following the first gabazine injection, measured during a 1-min interval centered around the peak of gabazine effect (peak vs. baseline: P ϭ 0.014). The XIIa AUC at the peak effect of the second gabazine injection was 8.40 Ϯ 2.52 V·min, representing a significant increase from baseline XIIa (P ϭ 0.043). However, the peak XIIa AUC was significantly lower after the second gabazine injection that was preceded by PF almorexant injection than after the first gabazine injection (8.40 Ϯ 2.52 vs. 10.31 Ϯ 2.48 V·min, P ϭ 0.038). The absolute increase of XIIa AUC from baseline to peak did not differ significantly between the first and second gabazine injections (8.49 Ϯ 2.31 vs. 6.31 Ϯ 2.34 V·min, P ϭ 0.16; Fig.  3A ). However, across the entire observation period of 70 min, the excitatory effect of gabazine was significantly attenuated when gabazine injection was preceded by almorexant injection into the PF hypothalamus (ANOVA, F 1,5 ϭ9.01, P ϭ 0.030) for the data set with XIIa AUC values relative to baseline levels prior to the first gabazine injection. The almorexant treatmentby-time interaction was significant (F 1,5,10 ϭ 3.44, P ϭ 0.002), and the post hoc, pairwise multiple comparisons revealed a significant 26 -44% suppression of the gabazine effect on XIIa AUC for all measurement intervals spanning the peak of gabazine effect (minutes 0 -35, P ϭ 0.007-0.037; Fig. 3C ). Similar findings were obtained when raw, nonnormalized XIIa AUC values were analyzed (almorexant effect across all gabazine postinjection time points: F 1,5 ϭ 6.98, P ϭ 0.046; alm-Orexinergic Transmission and Cardiorespiratory Excitation • Stettner GM et al. orexant treatment-by-time interaction: F 1,5,10 ϭ 2.07, P ϭ 0.045), and significant differences in the post hoc comparisons were found at each measurement interval following gabazine injection until minute 25 (P ϭ 0.003-0.041). Thus normalization of the data set yielded more significant measures of the effect of OX1R/OX2R antagonism on the response of XIIa to gabazine; however, both approaches yielded comparable results. The latency to the onset of gabazine effect on XIIa was significantly longer following PF almorexant injection (163 Ϯ 34 vs. 43 Ϯ 20 s, P ϭ 0.022), whereas the latency to the peak of gabazine effect only tended to be longer after PF almorexant injection (715 Ϯ 87 vs. 557 Ϯ 90 s, P ϭ 0.062; Fig. 3B ).
Central respiratory rate before first and second gabazine injection was 54.6 Ϯ 1.5 and 57.4 Ϯ 1.8 min Ϫ1 (P ϭ 0.18), respectively (Fig. 3D) . The increase of respiratory rate following PF gabazine injections was significant following both gabazine injections (first injection, to 69.8 Ϯ 2.0 min Ϫ1 , P ϭ 0.001; second injection, to 66.6 Ϯ 2.4 min Ϫ1 , P ϭ 0.024), but the difference between the baseline and peak respiratory rate tended to be lower following PF almorexant injection (15.2 Ϯ 2.3 vs. 9.2 Ϯ 2.9 min Ϫ1 , P ϭ 0.066; Fig. 3D ). The latencies to both the onset and peak of the gabazine effect on respiratory rate were significantly prolonged following PF almorexant injection (latency to onset: 121 Ϯ 24 vs. 26 Ϯ 12 s, P ϭ 0.022; latency to peak: 542 Ϯ 89 vs. 232 Ϯ 43 s, P ϭ 0.017; Fig. 3E ). PF almorexant attenuated the excitatory effect of hypothalamic gabazine on central respiratory rate over the entire observation period (Fig. 3F) . Since the respiratory rate data set was not normally distributed, a two-way, repeated-measures ANOVA could not be used. Instead, one-way, repeated-measures ANOVA was applied to a normally distributed data set containing absolute intraindividual differences between central respiratory rates within each measurement period following the first and second gabazine injections, followed by multiple post hoc comparisons of these differences to baseline conditions. This analysis revealed a significant effect of almorexant on the respiratory rate increase following gabazine injections (F 11 ϭ 3.85, P Ͻ 0.001), with the differences being significant for the measurement intervals between minute 0 and minute 20, and attenuation of the respiratory rate increase by 41-70% (P values ranging from Ͻ0.001 to 0.44).
The baseline heart rate before the first and second gabazine injections differed by 7.9 Ϯ 2.7 beats/min (446.0 Ϯ 6.2 vs. 453.9 Ϯ 6.7 beats/min, P ϭ 0.033; Fig. 3G ). Both gabazine injections led to a significant increase of the heart rate when peak levels were compared with the baseline (first injection, to 474.6 Ϯ 3.6 beats/min, P Ͻ 0.001; second injection, to 470.1 Ϯ 6.8 beats/min, P ϭ 0.007). The absolute increase of the heart rate from baseline to peak following PF gabazine injections was significantly lower following PF almorexant injection (16.2 Ϯ 3.7 vs. 28.7 Ϯ 3.9 beats/min, P ϭ 0.004; Fig. 3G ). The latency to onset of the gabazine effect was significantly prolonged following PF almorexant injection (69 Ϯ 20 vs. 282 Ϯ 89 s, P ϭ 0.048), whereas the latencies to the peak of gabazine effect did not differ (894 Ϯ 126 vs. 896 Ϯ 115 s, P ϭ 0.99; Fig.  3H ). Across all postgabazine measurement periods, the excitatory effect of hypothalamic gabazine on heart rate was significantly attenuated following PF almorexant injection (ANOVA, F 1,5 ϭ 22.30, P ϭ 0.005), with a significant 49 -82% suppression within each postinjection measurement period over the entire observation period (P ϭ 0.001-0.018; Fig.  3I ), and the almorexant treatment-by-time interaction was highly significant (ANOVA, F 1,5,10 ϭ 19.91, P Ͻ 0.001).
The mean arterial blood pressure was significantly higher during the baseline period before the first gabazine injection compared with the baseline before the second gabazine injection (66.9 Ϯ 6.1 vs. 57.9 Ϯ 7.3 mmHg, P ϭ 0.036; Fig. 3J ). Although the second measurement was taken 31 Ϯ 6 min following hypothalamic almorexant injection, the lower blood pressure level before the second gabazine injection was not caused by the hypothalamic almorexant injection, because the mean arterial blood pressure measured during a 1-min interval immediately before the almorexant injection (58.7 Ϯ 6.1 mmHg) did not differ from the baseline measured just before the second gabazine injection (P ϭ 0.77). A significant blood pressure increase was only elicited by the first gabazine injec-A B C D Fig. 1 . Distribution of gabazine injection sites in the perifornical (PF) region of the posterior hypothalamus superimposed onto three standard coronal sections (A-C) adapted from a rat brain atlas (46) . Each symbol corresponds to one animal [blue filled circles: gabazine injection sites in the 6 animals which had almorexant injected into the hypothalamic PF region before the second gabazine injection; red filled circles: gabazine injection sites in the 6 animals which had almorexant injected into the hypoglossal (XII) nucleus before the second gabazine injection]. D: example of one of the hypothalamic injection sites marked with Pontamine blue. The neutral red-stained section contains the track of the gabazine injection pipette filled with the blue dye and diffuse staining, which gradually fades from the center of the injection site located just dorso-medial to the fornix (f). The blue dye also accumulated alongside a vessel seen as an elongated shape located ventral to the f. 3V, third ventricle; ic, internal capsule; mt, mammillothalamic tract; opt, optic tract; PH, posterior hypothalamic nucleus; Sub, submedius thalamic nucleus; VM, ventromedial thalamic nucleus; VMH, ventromedial hypothalamic nucleus.
tion (increase to 73.2 Ϯ 6.1 mmHg, P ϭ 0.002), but not after the second gabazine injection following PF almorexant injection (increase to 58.4 Ϯ 8.0 mmHg, P ϭ 0.87). To test whether the baseline arterial blood pressure difference could be a confounding factor for other measures of the effect of gabazine, a correlation analysis was performed between the baseline blood pressure levels and relative baseline to peak changes from the first gabazine injections, including all 12 animals of this study. No significant correlation was found between the baseline blood pressure and the relative baseline to peak increases of XIIa AUC (r ϭ 0.32, P ϭ 0.32) or central respiratory rate (r ϭ 0.42, P ϭ 0.18). However, the mean arterial blood pressure was Fig. 2 . Example of the effect of disinhibition of neurons in the PF region of the posterior hypothalamus by local injection of the GABAA receptor antagonist, gabazine, on hippocampal activity, cortical EEG, central respiratory rate, hypoglossal nerve activity (XIIa), heart rate, and arterial blood pressure. A: continuous record covering 5 min of baseline activity and 105 min after gabazine injection. Injection of gabazine (20 nl, 0.18 mM) elicited a systemic response that included the following (from top): increase of the hippocampal signal power in the theta band (2.8 -4 Hz), increased amplitude of raw hippocampal signal, desynchronization of cortical EEG, acceleration of the central respiratory rate, increase of XIIa, which was mainly due to an increase of the phasic inspiratory XIIa, but contained also a tonic component [indicated by an upward shift of the baseline in the integrated XIIa (͐XIIa)], increased heart rate, and a mild increase of arterial blood pressure. The gabazine-evoked changes returned close to the baseline levels during the 105-min observation period. B-D: expanded, 10-s-long segments corresponding to the shaded areas in A show the raw hippocampal activity, cortical EEG, XIIa, and ͐XIIa during the baseline condition (B), at the peak of gabazine effect (C), and near the end of the record (D). Fig. 3 . Cardiorespiratory excitatory effects of gabazine injected into the PF hypothalamus are attenuated by microinjections of almorexant, a dual orexin 1 receptor/orexin 2 receptor antagonist, into the same hypothalamic site. The graphs in the left and middle columns compare the mean baseline and peak levels (ϮSE) of the investigated cardiorespiratory measures, absolute differences between baseline and peak activities, and the latencies to the onset and peak of gabazine effects between the first (shaded bars) and second gabazine injections (solid bars), with the second injection preceded by almorexant injection into the PF hypothalamus. Panels on the right show the entire average time course of cardiorespiratory changes elicited by gabazine over the 70-min observation period. The baseline and postgabazine mean values for each measurement period (5-min intervals from 5 min before to 40 min after gabazine injections and 10-min intervals thereafter) are plotted at the time corresponding to the end of each period (shaded open triangles: first gabazine injections; solid circles: second gabazine injections with almorexant pretreatment). A: mean baseline and peak ͐XIIa area under the curve (AUC) before and after hypothalamic gabazine injections. B: mean latencies to the onset and peak of gabazine effect on XIIa. C: effect of gabazine injections on ͐XIIa AUC over the entire observation period. D-L follow the identical order as A-C for the central respiratory rate (D-F), heart rate (G-I), and mean arterial blood pressure (J-L). Asterisks indicate significant differences between the effects of the first and second gabazine injections (*P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001); n ϭ 6 rats.
positively correlated with relative heart rate changes following gabazine injections (r ϭ 0.58, P ϭ 0.0498). This suggests that the baseline level of arterial blood pressure might have influenced the heart rate response to gabazine, and that almorexant alone might not be responsible for potential differences in heart rate effects elicited by the two gabazine injections. The difference between the mean blood pressure after the first and second gabazine injection was significant over the entire observation period (ANOVA, F 1,5 ϭ 17.61, P ϭ 0.009; Fig. 3L ), whereas the almorexant treatment-by-time interaction was not significant (ANOVA, F 1,5,10 ϭ 1.35, P ϭ 0.23). Consistent with this observation, a one-way, repeated-measures ANOVA applied to a data set containing absolute intraindividual differences between mean blood pressure levels within each measurement period following the first and second gabazine injections and the subsequent multiple post hoc comparisons of these differences to the baseline conditions revealed no significant effect of almorexant anywhere within the entire observation period (F 11 ϭ 1.2, P ϭ 0.33).
Impact of OX1R/OX2R antagonism in the XII nucleus on cardiorespiratory activation by gabazine injected into the PF hypothalamus. XIIa AUC was not significantly different between the baseline conditions before the first and second gabazine injections when measured in arbitrary units (0.76 Ϯ 0.19 vs. 1.03 Ϯ 0.31 V·min, P ϭ 0.27; Fig. 4A ). However, the baseline XIIa was significantly lower compared with the baseline XIIa in the previously described group of animals, which received almorexant injections into the PF hypothalamus (0.76 Ϯ 0.19 vs. 1.82 Ϯ 0.38 V·min, P ϭ 0.033). This difference could indicate subtle technical differences in the recording conditions or an increased responsiveness in the group with hypothalamic almorexant injections. To assess the latter possibility, we tested whether the baseline XIIa levels correlated with the responsiveness of different cardiorespiratory measures to gabazine, as measured by the relative baseline-to-peak changes following the first gabazine injections in all 12 animals of this study. We found no significant correlations between the baseline XIIa and the baseline to peak increase of XIIa AUC (r ϭ 0.14, P ϭ 0.66), central respiratory rate (r ϭ 0.15, P ϭ 0.64), or heart rate (r ϭ 0.33, P ϭ 0.30). Both PF gabazine injections led to a significant increase of the XIIa AUC when the peak levels were compared with baseline activities. XIIa AUC reached 4.12 Ϯ 1.79 V·min at the peak of the effect following the first gabazine injection (peak vs. baseline: P ϭ 0.031) and 3.56 Ϯ 1.42 V·min following the second gabazine injection with almorexant injected into the XII nucleus (peak vs. baseline: P ϭ 0.031). These peak activities following the first and second gabazine injections, respectively, were not significantly different (P ϭ 0.21; Fig. 4A ). The latencies to the onset and peak of gabazine effect on XIIa were not altered by almorexant (latency to onset: 201 Ϯ 65 vs. 204 Ϯ 79 s, P ϭ 0.97, and latency to peak: 884 Ϯ 160 vs. 748 Ϯ 110 s, P ϭ 0.017, for the first and second gabazine injection, respectively; Fig. 4B ). Over the entire 70-min observation period following each gabazine injection, the excitatory effect of gabazine was marginally smaller when gabazine injection was preceded by almorexant injections into the XII nucleus (ANOVA, F 1,5 ϭ 6.58, P ϭ 0.050) for the data set, with XIIa AUC values measured as the percentage of baseline XIIa AUC before the first gabazine injection. The almorexant treatment-by-time interaction was not significant (F 1,5,10 ϭ 0.87, P ϭ 0.57). Nevertheless, pairwise multiple comparisons revealed a significant, 38 -46% suppression (P ϭ 0.008 -0.027) of the gabazine effect on XIIa that was restricted to the second half of the observation period, well past the peak of gabazine effect (minutes 40 -70; Fig. 4C ). This almorexant effect was absent when the raw, nonnormalized XIIa AUC data set was used for the analysis (ANOVA, F 1,5 ϭ 3.74, P ϭ 0.11).
The central respiratory rates before the first and second gabazine injections showed a small but significant difference (50.1 Ϯ 1.7 vs. 54.0 Ϯ 1.9 min Ϫ1 , P ϭ 0.012; Fig. 4D ). Both PF gabazine injections led to a significant increase of the central respiratory rate when the peak levels were compared with the corresponding baselines (first injection, to 62.9 Ϯ 3.0 min Ϫ1 , P ϭ 0.022; second injection, to 65.6 Ϯ 2.9 min Ϫ1 , P ϭ 0.006). No significant differences between the effects of the first and second gabazine injection were observed for the absolute increase of respiratory rate from the baseline to peak (12.9 Ϯ 3.9 vs. 11.6 Ϯ 2.5 min Ϫ1 , P ϭ 0.53), latency to the onset of gabazine effect (133 Ϯ 57 vs. 228 Ϯ 65 s, P ϭ 0.056), latency to the peak of gabazine effect (499 Ϯ 110 vs. 690 Ϯ 73 s, P ϭ 0.21; Fig. 4E ), or the effect of almorexant injection assessed across the entire observation period (ANOVA, F 1,5 ϭ 0.0009, P ϭ 0.98; Fig. 4F ).
The heart rate at baseline before the first and second gabazine injections was not significantly different (477.3 Ϯ 7.8 vs. 484.9 Ϯ 3.9 beats/min, P ϭ 0.22; Fig. 4G ). Both gabazine injections led to a significant increase of the heart rate (first injection, to 501 Ϯ 5.7 beats/min, P ϭ 0.026; second injection, to 505.4 Ϯ 5.6 beats/min, P ϭ 0.019). No significant differences between the effects of the first and second gabazine injection were found for the absolute increase of the heart rate from the baseline to the peak (23.9 Ϯ 7.6 vs. 20.5 Ϯ 6.0 beats/min, P ϭ 0.28), latency to the onset of gabazine effect (194 Ϯ 89 vs. 207 Ϯ 67 s, P ϭ 0.64), latency to the peak of gabazine effect (938 Ϯ 89 vs. 1,125 Ϯ 160 s, P ϭ 0.31; Fig.  4H ), or the effect of almorexant injected into the XII nucleus across the entire observation period (ANOVA, F 1,5 ϭ 2.59, P ϭ 0.17; Fig. 4I ).
The mean arterial blood pressure at baseline before the first and second gabazine injections was not significantly different (53.0 Ϯ 3.9 vs. 51.9 Ϯ 6.4 mmHg, P ϭ 0.73; Fig. 4J ). The first gabazine injection led to a significant increase of blood pressure to 61.7 Ϯ 6.5 mmHg at the peak of gabazine effect (P ϭ 0.045), whereas the second gabazine injection following almorexant injection caused a smaller blood pressure increase, to 57.1 Ϯ 6.8 mmHg, that was not statistically significant (P ϭ 0.064). No significant differences between the effects of the first and second gabazine injection were found for the absolute increase of blood pressure from the baseline to the peak (8.7 Ϯ 3.3 vs. 5.2 Ϯ 2.2 mmHg, P ϭ 0.17), latency to onset of the effect (296 Ϯ 90 vs. 487 Ϯ 48 s, P ϭ 0.11), latency to the peak effect (724 Ϯ 106 vs. 743 Ϯ 54 s, P ϭ 0.99; Fig. 4K ), or the effect of almorexant injection into the XII nucleus assessed across the entire observation period (ANOVA, F 1,5 ϭ 1.45, P ϭ 0.28; Fig. 4L ).
DISCUSSION
We found that the excitatory effect of hypothalamic gabazine injections on XII motoneurons was significantly attenuated by almorexant, a dual OX1R/OX2R antagonist (9), when it was injected into the PF region of the hypothalamus, whereas (D-F) , heart rate (G-F), and mean arterial blood pressure (J-L). Asterisks indicate significant differences between the effects of the first and second gabazine injections (*P Ͻ 0.05, **P Ͻ 0.01); n ϭ 6 rats.
the effect was minimal and delayed when almorexant was injected into the XII nucleus. Similarly, the PF gabazineelicited acceleration of the central respiratory rate and heart rate were attenuated only when almorexant was injected into the PF region. Hypothalamic gabazine evoked a mild increase of the mean arterial blood pressure, which was reduced after hypothalamic almorexant injection when the peak effects were compared, but a more detailed analysis over the entire observation period did not reveal any significant impact of hypothalamic or XII nucleus almorexant injection on the gabazineelicited blood pressure changes. Collectively, these results show that XII motoneuronal activation, as well as acceleration of central respiratory rate and heart rate evoked from the PF region by antagonizing GABA A receptors, is mediated, in part, by OX-dependent activation that occurs within the PF region, rather than in the XII nucleus or adjacent medullary nuclei.
GABAergic sleep-active neurons of the anterior hypothalamus project to the PF region of the posterior hypothalamus, where they inhibit OX and other neurons (55) . In chronically instrumented, behaving rats, disinhibition of neurons in the PF region by GABA A receptor antagonists activates OX neurons and induces wakefulness (2, 29) . Also in urethane-anesthetized rats, a strong endogenous GABAergic inhibition of PF neurons, including OX neurons, is revealed by a systemic excitatory effect of PF microinjections of a GABA A receptor antagonist on XIIa, respiratory rate, and cortical and hippocampal activities (25, 26, 38) . Importantly, multiple PF injections of the GABA A receptor antagonist bicuculline in previous studies (26, 38) and gabazine in the present experiments with almorexant injections into the XII nucleus document that there is no inherent time-dependent decline of the magnitude of the effects elicited by repetitive GABA A receptor antagonist injections into the PF region. This provides the basis for comparison of the effects of two successive GABA A receptor antagonist injections in conjunction with other manipulations, such as antagonism of the OX transmission used in our study. Both OX and melanin-concentrating hormone (MCH) containing neurons are located in the PF region of the posterior hypothalamus (7, 15, 53, 57) , and both contribute to the regulation of sleep and metabolism (reviewed in Ref. 1). However, PF administration of GABA A receptor antagonists excites OX neurons and other cells within that area, but not MCH-expressing neurons (2, 29, 38) . This activation is accompanied by activation of XII motoneurons and increase of arterial blood pressure, heart rate, and respiratory rate (16, 18, 19, 25, 26, 38, 65) . The XII motoneuronal excitation is, in part, dependent on OX pathways because systemic administration of almorexant significantly attenuated this effect (26) . Our subsequent study of the pathway interposed between the PF region and XII motoneurons indicated that excitatory noradrenergic and serotonergic projections to the XII nucleus are not required for this activation (25) . Therefore, the aim of this study was to investigate two other potential pathways, namely an indirect pathway involving local OX transmission within the PF hypothalamus and a direct OX pathway from the PF hypothalamus to XII motoneurons.
The current literature provides some evidence that disinhibition of neurons within the PF hypothalamus elicits local excitatory effects that are OX dependent. First, the PF region has a high density of OX-containing terminals (45, 48) . Second, both OX1R and OX2R are expressed throughout the posterior hypothalamus (41) . Third, OX directly excites OX neurons through OX2R (67) . This leads us to hypothesize that OX neurons not only stimulate other local cells within the PF region, but also strengthen and prolong their own activity as a first transmissional step in a multisynaptic pathway from the PF hypothalamus to XII motoneurons and other sites important for cardiorespiratory regulation. The results of our study support this hypothesis because dual OX1R/OX2R antagonism in the PF region significantly attenuated the excitatory effect of PF gabazine on XIIa, respiratory rate, and heart rate. On the other hand, PF almorexant did not entirely abolish the excitatory effects of PF gabazine. Indeed, the magnitude of attenuation observed in our present study was similar to that obtained with systemic almorexant administration (26) and showed a 26% reduction of XIIa AUC increase at the peak of the gabazine effect and at most a 44% reduction during the entire observation period following PF almorexant injection. This is similar to a 46% reduction of XIIa amplitude increase at the peak of the gabazine effect following systemic almorexant administration (26) . The similarity of the magnitudes of the systemic and local PF almorexant application on XII motoneuronal excitation suggests that the PF region is the main site where OX-dependent transmission contributes to these effects. However, these findings also indicate that OX-independent neuronal circuits and transmitter systems are responsible for about one-half of the excitatory effects of PF gabazine injections. Indeed, GABA A receptor antagonists injected into the PF hypothalamus excite many non-OX neurons (2, 29, 38) . The cells that are excited are not the MCH-containing neurons (2, 29, 38) , but otherwise the identity of these cells is not known. However, it is known that the PF hypothalamus contains glutamatergic neurons (70), of which some have direct projections to the trigeminal motor nucleus (42) . Whether PF gabazine injections excite these glutamatergic neurons and whether these neurons also have direct projections to XII motoneurons needs to be determined, because such a glutamatergic hypothalamo-XII pathway may importantly contribute to the excitatory effect of PF disinhibition on XII motoneurons.
Interestingly, direct projections of OX neurons to XII motoneurons, albeit anatomically well documented (27, 42, 45, 48) , did not have any detectable contribution to the excitatory effects of PF gabazine on XII motoneuronal activation, because dual OX1R/OX2R antagonism in the XII nucleus did not attenuate the excitatory effect of PF gabazine. Thus the direct OX pathway to the XII nucleus plays a minimal role or is inactive in urethane-anesthetized rats, because we found only a trend toward a reduced activation of XIIa at the tail end of the long-lasting gabazine effect. Considering the long latency, this effect may have been elicited from OX-sensitive sites to which almorexant gradually diffused from the original injection site within the XII nucleus. Candidates in the vicinity of the XII nucleus that have a potential to influence XII motoneuronal activity include the XII premotoneurons located in the medullary reticular formation ventrolateral to the XII nucleus and cells of the nucleus of the solitary tract located dorsal to the XII nucleus (20, 66) , because both sites have moderate levels of OX2R mRNA (41) .
Disinhibition of PF neurons also elicited acceleration of the central respiratory rate and heart rate and evoked a mild but significant increase of the mean arterial blood pressure, as described previously (18, 32, 38) . The excitatory effect of PF gabazine on these cardiorespiratory measures was also attenuated by almorexant injections into the PF hypothalamus. The attenuation was especially prominent for the central respiratory rate and heart rate, whereas our results only weakly supported the effect of PF almorexant on gabazine-elicited blood pressure changes. Interestingly, the cardiorespiratory excitation in urethane-anesthetized OX knockout mice following PF disinhibition with bicuculline was significantly lower compared with that of wild-type mice (32, 33) , which is consistent with our results. Thus these studies all demonstrate a contribution of the OX system to cardiorespiratory activation from the PF region, but they also point to other major excitatory, OX-independent pathways from the PF hypothalamus to brain stem cardiorespiratory sites.
The attenuation by PF almorexant of the respiratory rate and heart rate effects of gabazine suggests that local PF synaptic transmission from OX neurons to other neurons within the PF region is part of a multisynaptic pathway linking the PF hypothalamus to cardiorespiratory outputs. This is not the sole OX-dependent pathway, because injection of OX into the rostral ventrolateral medulla, an area that contains the adrenergic C1 cell group important for cardiovascular activation, elicits a similar cardiovascular response in behaving and anesthetized rats (12, 39) as that elicited by disinhibition of PF neurons (18, 32, 38) . The excitation by OX of the respiratory system may occur at several distinct sites within the pontomedullary respiratory network (reviewed in Ref. 28 ). For example, OX administered into the rostral part of the medullary ventral respiratory column aiming at the region of the pre-Bötzinger complex increased diaphragmatic activity without affecting the respiratory rate (69), whereas OX injections into the pontine Kölliker-Fuse nucleus increased the respiratory rate (21) . Since both sites contain OX terminals and receptors (41, 45, 48) , an indirect pathway from the PF region to the XII nucleus might include the pontomedullary respiratory network. This may explain the increase of XIIa and acceleration of the central respiratory rate elicited by PF gabazine and attenuation of these effects by PF almorexant.
The sleep-promoting effect of OX receptor antagonists prompted considerable interest in the utility of this class of drugs for treatment of insomnia (56) . Accordingly, the findings of our study are of potential clinical relevance for the use of this class of drugs in patients with OSA. OSA patients experience repetitive upper airway narrowing or collapse and hypoxic episodes during sleep that disrupt both sleep and ventilation (see Ref. 17 for review). However, when awake, hyperactivity of upper airway muscles, including those of the tongue (43, 60) , protects the upper airway of OSA patients against occlusions and allows for adequate ventilation. A potential mechanism leading to the protective upper airway muscle hyperactivity during wakefulness, as derived from investigations in rats exposed to chronic intermittent hypoxia, may involve an increased endogenous noradrenergic and serotonergic drive to XII motoneurons (51, 58) . Our data suggest that, in OSA patients, OX antagonists may impair the ability to maintain adequate activation of upper airway muscles. What still remains to be determined is whether and how the endogenous OX-dependent activation of upper airway motoneurons is altered in this patient population.
Systemic (26) and local PF (this study) administration of a dual OX1R/OX2R antagonist reduced the excitatory effect of PF hypothalamic neurons on XIIa. A reduction of the excitatory effect of wake-active OX neurons on XII motoneurons in OSA patients might weaken the protective upper airway mechanism during wakefulness and/or reduce the effectiveness of arousal-related upper airway activation that these patients often need to resolve upper airway obstruction. In addition, OX receptor antagonism may reduce inspiratory drive to upper airway motoneurons in OSA patients, because disruption of OX transmission reduces the central CO 2 sensitivity in wakefulness (Ref. 34 , reviewed in Refs. 35, 36) . On the other hand, the finding that noradrenergic and serotonergic activation of XII motoneurons can be dissociated from the excitatory effects elicited in XII motoneurons from the PF region of the posterior hypothalamus suggests that the compensatory, wake-related hyperactivity of upper airway muscles in OSA patients may develop independently of the OX system. Thus it will be important to determine whether the conditions characteristic of OSA, such as chronic intermittent hypoxia or sleep loss and fragmentation, influence the excitatory OX transmission to XII motoneurons.
